Analysts expect that Prothena Corp (NASDAQ:PRTA) will announce $270,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Prothena’s earnings, with estimates ranging from $200,000.00 to $390,000.00. Prothena posted sales of $26.81 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 99%. The business is expected to announce its next quarterly earnings results on Tuesday, August 14th.
On average, analysts expect that Prothena will report full-year sales of $1.07 million for the current financial year, with estimates ranging from $900,000.00 to $1.40 million. For the next financial year, analysts anticipate that the company will post sales of $66.16 million per share, with estimates ranging from $25.95 million to $121.63 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Prothena.
Prothena (NASDAQ:PRTA) last announced its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($1.26) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.03). The firm had revenue of $0.23 million during the quarter, compared to the consensus estimate of $31.45 million. Prothena had a negative net margin of 606.09% and a negative return on equity of 38.08%.
Large investors have recently bought and sold shares of the company. HBK Investments L P bought a new position in shares of Prothena in the 4th quarter worth $213,000. LPL Financial LLC bought a new position in shares of Prothena in the 1st quarter worth $210,000. Aperio Group LLC bought a new position in shares of Prothena in the 1st quarter worth $222,000. Oppenheimer & Co. Inc. bought a new position in shares of Prothena in the 1st quarter worth $284,000. Finally, Jefferies Group LLC bought a new position in shares of Prothena in the 4th quarter worth $292,000.
Shares of Prothena opened at $15.60 on Friday, according to Marketbeat. The firm has a market capitalization of $656.27 million, a price-to-earnings ratio of -3.83 and a beta of 2.77. Prothena has a 52 week low of $16.31 and a 52 week high of $16.81.
Prothena Company Profile
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.